Abcuro
PrivateLast Round
Series D
Aug 7, 2026
Total Funding Raised
$407.25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Abcuro operates in Healthcare & Life Sciences and is based in Newton, Massachusetts. Its latest recorded funding round was a Series C round in February 2025.
Abcuro is a biotechnology company that develops immunomodulatory therapeutics aimed at treating autoimmunity and cancer through innovative analysis of transcription data to target critical immune system components.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abcuro Comparables
Compare Abcuro with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HiFiBiO Therapeutics | 86% | |
| Dren Bio | 79% | |
| Santa Ana Bio | 72% |
For institutional investors. Book with your work email.
Abcuro Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 7, 2026 | ||||
| Series C | Feb 12, 2025 | ||||
| Series B | Aug 17, 2023 | ||||
| Series A Extension | Jan 7, 2021 | ||||
| Series A | Nov 9, 2018 | ||||
Seed | Dec 13, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Abcuro Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D, Series B |
| Soleus Capital | Series D, Series C, Series B |
| Bain Capital Life Sciences | Series D, Series C, Series B |
| RA Capital Management | Series D, Series C, Series A Extension, Series B |
| New Leaf Venture Partners | Series C, Series B, Series D |
| New Enterprise Associates | Series D, Series C |
| Kaitai Capital | Series D, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 59% MoM, reaching 3.9K.
- Aug 7, 2026
Raised $39.4M in early stage VC funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- goes_publicSep 8, 2026
Abcuro prepares for an initial public offering in anticipation of positive Phase 2/3 results in Feb '26.
- launchesAug 20, 2026
Abcuro plans to launch a new Phase 3 trial of ulviprubart (ABC008) after securing additional funding and discussing a path forward with the U.S. Food and Drug Administration, with the study expected to focus on people with less advanced inclusion body myositis.
- receives_financingAug 19, 2026
Abcuro announced the closing of a $66M Series D financing in Massachusetts on Aug 18th '26, led by New Leaf Venture Partners with participation from existing investors and Rock Springs Capital to support a potentially registrational ulviprubart study in inclusion body myositis.
For institutional investors. Book with your work email.
Abcuro Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Abcuro's valuation, stock price, and market status.
Is Abcuro a public or private company?
Abcuro is a private company.
What is the current stock price of Abcuro?
Abcuro is a private company, so its shares have no public market price. Caplight tracks Abcuro's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abcuro worth (valuation)?
Valuation information for Abcuro is not publicly available.
Can I buy Abcuro stock?
Abcuro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abcuro's last funding round?
Abcuro's most recent funding round was Series D on August 7, 2026.
Who are the main investors in Abcuro?
Key investors in Abcuro include Redmile Group, Bain Capital Life Sciences, New Leaf Venture Partners, New Enterprise Associates, Kaitai Capital.
Will Abcuro IPO soon?
No public IPO plans have been announced for Abcuro.
How can I track Abcuro secondary market activity?
Caplight tracks bids, offers, and trades in Abcuro's shares on secondary markets.